Sage Therapeutics CNS disorder treatment patent
Summary
The EPO published patent application EP3728285A1 by Sage Therapeutics LLC for pharmaceutical compositions and methods treating central nervous system disorders. The application covers steroid-based formulations classified under A61K 31/57 and designates 32 European member states including major markets.
What changed
The EPO published patent application EP3728285A1 on April 1, 2026, filed by Sage Therapeutics LLC. The application covers compositions and methods for treating CNS disorders using steroid-based formulations classified under A61K 31/57 with A61P 25/00 therapeutic indication. Designated states include all EU member states plus CH, LI, MC, TR, AL, IS, NO, RS, MK.
Pharmaceutical companies developing CNS disorder treatments should monitor this publication for potential freedom-to-operate implications in European markets. Competitors in the neuropharmaceutical space should review the claims to assess overlap with their own pipeline candidates or approved therapies.
What to do next
- Monitor for patent grant or opposition period
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
Publication EP3728285A1 Kind: A1 Apr 01, 2026
Applicants
Sage Therapeutics, LLC
Inventors
ROBICHAUD, Albert, Jean, SALITURO, Francesco, G., BLANCO-PILLADO, Maria, Jesus, LA, Daniel, HARRISON, Boyd, L.
IPC Classifications
C07J 63/00 20060101AFI20190628BHEP C07J 61/00 20060101ALI20190628BHEP A61K 31/57 20060101ALI20190628BHEP A61P 25/00 20060101ALI20190628BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.